Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution)

- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder


- LIVMARLI is the first and only...

Related Keywords

Canada , Toronto , Ontario , Canadian , Binita Kamath , Chris Peetz , Roberta Smith , Intrahepatic Cholestasis , Drug Administration , Alagille Syndrome Alliance , Instagram , Twitter , Linkedin , Health Canada , Canadian Agency For Drugs , Mirum Pharmaceuticals Inc , Technologies In Health , Canadian Drug Expert Committee , Nasdaq , Hepatology Program , European Commission , Mirum Pharmaceuticals , Canadian Agency , Alagille Syndrome , Senior Associate Scientist , Sick Children , Progressive Familial Intrahepatic Cholestasis , Breakthrough Therapy , Fat Soluble Vitamin , Markets ,